238 related articles for article (PubMed ID: 28285691)
1. Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer-Incidence, radiological features and clinical characteristics.
Halpenny DF; McEvoy S; Li A; Hayan S; Capanu M; Zheng J; Riely G; Ginsberg MS
Lung Cancer; 2017 Apr; 106():33-36. PubMed ID: 28285691
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib Associated Renal Cysts [CARCs]: incidence and patterns of evolution.
Cameron LB; Jiang DH; Moodie K; Mitchell C; Solomon B; Parameswaran BK
Cancer Imaging; 2017 Feb; 17(1):7. PubMed ID: 28209203
[TBL] [Abstract][Full Text] [Related]
3. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer.
Lin YT; Wang YF; Yang JC; Yu CJ; Wu SG; Shih JY; Yang PC
J Thorac Oncol; 2014 Nov; 9(11):1720-5. PubMed ID: 25436806
[TBL] [Abstract][Full Text] [Related]
4. Complex renal cysts associated with crizotinib treatment.
Schnell P; Bartlett CH; Solomon BJ; Tassell V; Shaw AT; de Pas T; Lee SH; Lee GK; Tanaka K; Tan W; Tang Y; Wilner KD; Safferman A; Han JY
Cancer Med; 2015 Jun; 4(6):887-96. PubMed ID: 25756473
[TBL] [Abstract][Full Text] [Related]
5. Infected complex renal cysts during crizotinib therapy in a patient with non-small cell lung cancer positive for ALK rearrangement.
Yoneshima Y; Okamoto I; Arimura-Omori M; Kimura S; Hidaka-Fujimoto N; Iwama E; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Apr; 33(2):510-2. PubMed ID: 25433426
[TBL] [Abstract][Full Text] [Related]
6. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
7. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
Taima K; Tanaka H; Tanaka Y; Itoga M; Takanashi S; Tasaka S
Intern Med; 2017 Sep; 56(17):2321-2324. PubMed ID: 28794366
[TBL] [Abstract][Full Text] [Related]
8. [Renal cysts - A novel complication of crizotinib treatment for lung cancer].
CsToth I; Meert AP; Sculier JP; Berghmans T
Rev Mal Respir; 2015 Nov; 32(9):956-8. PubMed ID: 26033699
[TBL] [Abstract][Full Text] [Related]
9. Development of complex renal cysts: A complication associated with Crizotinib therapy.
Chen F; Patel NJ; Legout JD; Caserta MP
Clin Imaging; 2020 Sep; 65():15-17. PubMed ID: 32353713
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
11. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
13. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
14. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Duruisseaux M; Besse B; Cadranel J; Pérol M; Mennecier B; Bigay-Game L; Descourt R; Dansin E; Audigier-Valette C; Moreau L; Hureaux J; Veillon R; Otto J; Madroszyk-Flandin A; Cortot A; Guichard F; Boudou-Rouquette P; Langlais A; Missy P; Morin F; Moro-Sibilot D
Oncotarget; 2017 Mar; 8(13):21903-21917. PubMed ID: 28423535
[TBL] [Abstract][Full Text] [Related]
15. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
16. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib-induced pancreatic pseudocyst: a novel adverse event.
Ishida H; Ichikawa W; Sasaki Y
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26351314
[TBL] [Abstract][Full Text] [Related]
18. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; Barón AE; Chonchol M; Camidge DR
Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]